Allergan Shareholders Approve Proposed Acquisition by AbbVie

AbbVie acquires Allergan: unpicking the year-long approval process

AbbVie's $63bn acquisition of Allergan has been in the works since June 2019. It aims to diversify AbbVie's portfolio beyond its blockbuster product Humira.

AbbVie Completes Acquisition of Allergan - Eyewire News

AbbVie announced that it has completed its acquisition of Allergan after receiving regulatory approval from all government authorities.

FORM 8-K - Abbvie Investor Relations

... proposed Acquisition. The Transaction Agreement ... shareholders and requires the board of directors of Allergan to recommend approval of the Acquisition.

AbbVie to Acquire Cerevel Therapeutics in Transformative ...

The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved ...

AbbVie to Acquire Allergan for $63 Billion - Pharma's Almanac

Under the terms of the Transaction Agreement, Allergan Shareholders will receive 0.8660 AbbVie Shares and $120.30 in cash for each Allergan ...

AbbVie Inc. completed the acquisition of Allergan plc from its ...

AbbVie Inc. agreed to acquire Allergan plc from its Directors, Morgan Stanley AIP GP LP, Morgan Stanley Investment Management Inc. and other shareholders ...

AbbVie to Acquire ImmunoGen, including its Flagship Cancer ...

This transaction is expected to close in the middle of 2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other ...

Allergan shareholders back planned takeover by AbbVie - LinkedIn

Allergan announced Monday that its shareholders have voted in favour of approving AbbVie's proposed $63-billion acquisition of the company.

Three factors that drove the transformational integration of AbbVie ...

On May 8, 2020, the new AbbVie was created. That day, AbbVie officially closed its $63-billion acquisition of Allergan to create a larger, ...

Allergan shareholders approve $63bn Abbvie acquisition

The shareholders of Irish pharmaceutical company Allergan have approved the $63bn acquisition by Botox manufacturer Abbvie.

Allergan shareholders okays USD 63 billion AbbVie acquisition

New Delhi: Allergan plc recently announced that its shareholders have voted to approve ... proposed acquisition of Allergan by AbbVie Inc ("AbbVie ...

AbbVie-Allergan's $63B merger secures Irish court approval

AbbVie Inc.'s proposed $63 billion acquisition of Allergan PLC has been approved by the Irish High Court, pushing the companies a step ...

AbbVie's premium bid for Allergan isn't enough for one investor ...

In a New Jersey lawsuit, shareholder YuanLan Swei says the proxy statement detailing AbbVie's proposed Allergan buyout omits key info for ...

News - AbbVie News Center

All news · October 14, 2019. Allergan Shareholders Approve Proposed Acquisition by AbbVie · October 11, 2019 · October 10, 2019 · October 09, 2019 · October 08, 2019.

AbbVie (ABBV) Announces Agreement to Acquire Allergan (AGN) in ...

AbbVie (ABBV) Announces Agreement to Acquire Allergan (AGN) in $63 Billion Deal · New growth platforms and leadership positions to diversify and ...

Botox maker Allergan bought by US drug giant for $63bn

Its bestseller Humira will lose patent protection in 2023, which means other drugmakers can make cheaper generic versions. AbbVie shareholders ...

Expert Q&A on Health Care Mergers and Acquisitions

AbbVie Inc.'s proposed $63 billion acquisition of Allergan plc is one of the largest health care mergers announced in 2019. Practical Law asked Igor Kirman ...

AbbVie's Allergan Acquisition Sowed Doubts, but Some Analysts ...

Shares of AbbVie have been inching back up a week after they plunged 16% on news of the company's planned acquisition of Allergan. The stock has ...

AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal

AbbVie is offering $120.30 in cash and 0.866 of its shares for each share of Allergan. The offer price, total of cash and stock, represents a ...

Allergan Issues Update On AbbVie Deal - Quick Facts - Nasdaq

On January 10, AbbVie and Allergan received conditional approval from the European Commission for AbbVie's proposed acquisition of Allergan.